BOSTON (April 27, 2009) --In an in vitro study, led by Grace Gill, PhD, Tufts University School of Medicine, researchers discovered how a protein called SUMO (Small Ubiquitin-related Modifier) guides an enzyme complex that alters the structure of chromatin to regulate expression of genes. Chromatin is a compacted mass of DNA and protein that make up chromosomes. The interaction between SUMO and the enzyme complex is of interest in the study of cancer and neurodegenerative diseases such as Alzheimer's, where aberrant gene expression and altered SUMO function are thought to be indicative of disease.
The protein called SUMO is known to chemically modify other proteins, called transcription factors, which in turn enables the meticulous regulation of genes. Gene regulation is a fundamental biological process that allows necessary genes to be turned on or off in specific cell types.
The researchers found that SUMO interacts with an enzyme complex (LSD1/CoREST/HDAC) that alters chromatin structure to regulate genes within cells. The researchers found that the interaction between SUMO and this enzyme complex is responsible for preventing aberrant expression. Aberrant gene expression is a common feature of cancer and other disorders and altered SUMO processes might contribute to neurodegeneration.
"We've only known for about 10 years that SUMO chemically modifies proteins. We have a good understanding of how SUMO modifies other proteins, but the actual mechanism of how this modification alters cell function is not well known. Our study uncovers a fundamental aspect of how SUMO works, which has implications for many diseases. Until now, SUMO and LSD1/CoREST/HDAC have not been studied together; we've found out how they work together to turn off certain genes," says Gill.
The Gill Lab is continuing to investigate SUMO-dependent cell activity to delineate the complex genetic mechanisms that support gene regulation.
First author Jian Ouyang, PhD, is a postdoctoral associate in Gill's lab, formerly in the department of pathology at Harvard Medical School.
Senior author Grace Gill, PhD, is an associate professor at Tufts University School of Medicine and a member of the genetics and cell, molecular and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts, formerly in the department of pathology at Harvard Medical School.
This study was supported by an award from the Carolyn and Peter S. Lynch Endowed Research Fund (to Harvard Medical School) and a grant from the National Institute of General Medical Sciences at the National Institutes of Health.
Ouyang J, Shi Y, Valin A, Xuan Y, and Gill G. Molecular Cell. 2009 (April 24); 34(2): 145-154. "Direct Binding of CoREST1 to SUMO-2/3 Contributes to Gene-Specific Repression by the LSD1/CoREST1/HDAC Complex." Published online April 23, 2009, doi: 10.1016/j.molcel.2009.03.013
About Tufts University School of Medicine
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.
If you are a member of the media interested in learning more about this topic, or speaking with a faculty member at the Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences, or another Tufts health sciences researcher please contact Siobhan Gallagher at 617-636-6586 or, for this specific study, Crissanka Christadoss at 617-636-2789.